中国生物制药收购浩欧博股权设定利润承诺

财中社
18 Nov 2024

  财中社11月18日电中国生物制药(01177)发布补充公告,涉及收购江苏浩欧博生物医药股份有限公司29.99%股权的相关信息。公告指出,海瑞祥天生物科技香港承诺在2024年至2026财年,母公司股东应占目标公司的纯利分别不得低于4970万元、5218万元及5479万元;同时,扣除特别损益后的纯利承诺为4547万元、4774万元及5013万元。

  此外,公告还明确了利润承诺的计定基准和不遵守的后果。如果任何财年实际纯利低于承诺,海瑞祥天生物科技香港需以现金方式补偿差额,最高责任不超过8000万元。公司将遵守上市规则的相关披露要求,确保对利润承诺的变动进行及时更新。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10